{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T02:25:50Z","timestamp":1791599150067,"version":"4.3.4"},"reference-count":78,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T00:00:00Z","timestamp":1539129600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["568807"],"award-info":[{"award-number":["568807"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.02230","type":"journal-article","created":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T10:23:14Z","timestamp":1539166994000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":111,"title":["C-Reactive Protein: Higher During Acute Psychotic Episodes and Related to Cortical Thickness in Schizophrenia and Healthy Controls"],"prefix":"10.3389","volume":"9","author":[{"given":"Isabella","family":"Jacomb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive","family":"Stanton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohini","family":"Vasudevan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryanne","family":"O'Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhoshel","family":"Lenroot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Bruggemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Balzan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cherrie","family":"Galletly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia S.","family":"Weickert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas W.","family":"Weickert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,10,10]]},"reference":[{"key":"B1","volume-title":"Diagnostic and Statistical Manual of Mental Disorders.","author":"American","year":"2013"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1155\/2013\/510402","article-title":"Biomarkers in schizophrenia: A brief conceptual consideration","volume":"35","author":"Weickert","year":"2013","journal-title":"Dis Markers"},{"key":"B3","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.psc.2016.01.011","article-title":"What's hot in schizophrenia research?","volume":"39","author":"Weickert","year":"2016","journal-title":"Psychiatr Clin North Am"},{"key":"B4","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1007\/s11481-013-9462-8","article-title":"Evidence for a dysregulated immune system in the etiology of psychiatric disorders","volume":"8","author":"Gibney","year":"2013","journal-title":"J Neuroimmune Pharmacol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.biopsych.2013.06.010","article-title":"Immune system disturbances in schizophrenia","volume":"75","author":"Horvath","year":"2014","journal-title":"Biol Psychiatry"},{"key":"B6","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1159\/000356538","article-title":"Immunology of schizophrenia","volume":"21","author":"Muller","year":"2014","journal-title":"Neuroimmunomodulation"},{"key":"B7","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1176\/appi.ajp.2009.09030361","article-title":"Prenatal infection and schizophrenia: a review of epidemiologic and translational studies","volume":"167","author":"Brown","year":"2010","journal-title":"Am J Psychiatry"},{"key":"B8","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1176\/appi.ajp.2013.13010086","article-title":"A nationwide study on the risk of autoimmune diseases in individuals with a personal or a family history of schizophrenia and related psychosis","volume":"171","author":"Benros","year":"2014","journal-title":"Am J Psychiatry"},{"key":"B9","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1192\/bjp.bp.111.092098","article-title":"Prevalence of autoimmune diseases in in-patients with schizophrenia: nationwide population-based study","volume":"200","author":"Chen","year":"2012","journal-title":"Br J Psychiatry"},{"key":"B10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0278-5846(01)00221-4","article-title":"Cytokine profiles in schizophrenic patients treated with risperidone: a 3-month follow-up study","volume":"26","author":"Cazzullo","year":"2002","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"B11","doi-asserted-by":"publisher","first-page":"940","DOI":"10.4088\/JCP.v65n0710","article-title":"Changes in serum interleukin-2,\u22126, and\u22128 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia","volume":"65","author":"Zhang","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.biopsych.2009.06.005","article-title":"Inflammatory markers in schizophrenia: comparing antipsychotic effects in Phase 1 of the CATIE Schizophrenia Trial","volume":"66","author":"Meyer","year":"2009","journal-title":"Biol Psychiatry"},{"key":"B13","doi-asserted-by":"publisher","first-page":"520","DOI":"10.4088\/JCP.09m05117yel","article-title":"Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial","volume":"71","author":"Laan","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1176\/appi.ajp.159.6.1029","article-title":"Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia","volume":"159","author":"Muller","year":"2002","journal-title":"Am J Psychiatry"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1177\/0269881112444941","article-title":"Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment","volume":"26","author":"Chaudhry","year":"2012","journal-title":"J Psychopharmacol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"138","DOI":"10.4088\/JCP.08m04666yel","article-title":"A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia","volume":"71","author":"Levkovitz","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"B17","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/mp.2012.110","article-title":"Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia","volume":"18","author":"Fillman","year":"2013","journal-title":"Mol Psychiatry"},{"key":"B18","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.biopsych.2007.09.024","article-title":"Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review","volume":"63","author":"Potvin","year":"2008","journal-title":"Biol Psychiatry"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1176\/appi.ajp.2015.15010019","article-title":"Molecular mechanisms and timing of cortical immune activation in schizophrenia","volume":"172","author":"Volk","year":"2015","journal-title":"Am J Psychiatry"},{"key":"B20","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.bbi.2012.08.016","article-title":"Total and differential white blood cell counts, high-sensitivity C-reactive protien, and the metabolic syndrome in non-affective psychoses","volume":"31","author":"Miller","year":"2013","journal-title":"Brain Behav Immun"},{"key":"B21","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/0924-9338(96)82334-0","article-title":"Antinuclear antibodies in schizophrenia and major depressive disorder - A lasting puzzle","volume":"11","author":"Schott","year":"1996","journal-title":"Eur Psychiatry"},{"key":"B22","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/j.1600-0447.1995.tb09581.x","article-title":"Antinuclear autoantibodies in chronic schizophrenia","volume":"92","author":"Spivak","year":"1995","journal-title":"Acta Psychiatr Scand"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.2147\/NDT.S110484","article-title":"Relationship between neutrophil\/lymphocyte ratio with oxidative stress and psychopathology in patients with schizophrenia","volume":"12","author":"Kulaksizoglu","year":"2016","journal-title":"Neuropsychiatr Dis Treat"},{"key":"B24","first-page":"220","article-title":"Elevated neutrophil\/lymphocyte ratio in patients with schizophrenia","volume":"26","author":"Semiz","year":"2014","journal-title":"Psychiatr Danub"},{"key":"B25","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/mp.2015.87","article-title":"C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications","volume":"21","author":"Fernandes","year":"2016","journal-title":"Mol Psychiatry"},{"key":"B26","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.psychres.2014.02.004","article-title":"Role of C-reactive protein in schizophrenia: an overview","volume":"216","author":"Singh","year":"2014","journal-title":"Psychiatry Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.biopsych.2014.05.023","article-title":"Progressive reduction in cortical thickness as psychosis develops: a multisite longitudinal neuroimaging study of youth at elevated clinical risk","volume":"77","author":"Cannon","year":"2015","journal-title":"Biol Psychiatry"},{"key":"B28","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1093\/schbul\/sbu099","article-title":"Towards a psychosis risk blood diagnostic for persons experiencing high-risk symptoms: preliminary results from the NAPLS project","volume":"41","author":"Perkins","year":"2015","journal-title":"Schizophr Bull"},{"key":"B29","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1159\/000356536","article-title":"First-episode psychosis: an inflammatory state?","volume":"21","author":"Zajkowska","year":"2014","journal-title":"Neuroimmunomodulation"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1038\/mp.2015.90","article-title":"Elevated peripheral cytokines characterize a subgroup of people with schizophrenia displaying poor verbal fluency and reduced Broca's area volume","volume":"21","author":"Fillman","year":"2016","journal-title":"Mol Psychiatry"},{"key":"B31","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","article-title":"Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects","volume":"70","author":"Miller","year":"2011","journal-title":"Biol Psychiatry"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1172\/JCI200318921","article-title":"C-reactive protein: a critical update","volume":"111","author":"Pepys","year":"2003","journal-title":"J Clin Invest."},{"key":"B33","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3949\/ccjm.56.2.126","article-title":"C-reactive protein: the best laboratory indicatory available for monitoring disease activity","volume":"56","author":"Deodhar","year":"1989","journal-title":"Cleve Clin J Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.amjmed.2004.02.006","article-title":"Inflammation and atherosclerosis: role of C-reactive protein in risk assessment","volume":"116","author":"Libby","year":"2004","journal-title":"Am J Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"C19","DOI":"10.1016\/j.jacc.2005.10.066","article-title":"C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients","volume":"47","author":"Tsimikas","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3371\/CSRP.MICU.020813","article-title":"C-Reactive protein levels in schizophrenia: a review and meta-analysis","volume":"7","author":"Miller","year":"2014","journal-title":"Clin Schizophr Relat Psychoses"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/S0140-6736(09)60447-5","article-title":"Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial","volume":"373","author":"Ridker","year":"2009","journal-title":"Lancet"},{"key":"B38","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.bbi.2016.09.008","article-title":"Serum C-reactive protein in adolescence and risk of schizophrenia in adulthood: a prospective birth cohort study","volume":"59","author":"Metcalf","year":"2017","journal-title":"Brain Behav Immun"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1093\/schbul\/sbw029","article-title":"Chronic peripheral inflammation is associated with cognitive impairment in schizophrenia: results from the multicentric FACE-SZ dataset","volume":"42","author":"Bulzacka","year":"2016","journal-title":"Schizophr Bull"},{"key":"B40","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.schres.2007.03.022","article-title":"C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia","volume":"93","author":"Dickerson","year":"2007","journal-title":"Schizophr Res"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12888-016-0769-x","article-title":"The serum level of C-reactive protein (CRP) is associated with cognitive performance in acute phase psychosis","volume":"16","author":"Johnsen","year":"2016","journal-title":"BMC Psychiatry"},{"key":"B42","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.psychres.2006.07.011","article-title":"Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia","volume":"149","author":"Fan","year":"2007","journal-title":"Psychiatry Res"},{"key":"B43","first-page":"6","article-title":"C-reactive protein (CRP) in patients with schizophrenia: are they related with symptomatology?","volume":"15","author":"Solanki","year":"2009","journal-title":"J Mental Health Hum Behav."},{"key":"B44","first-page":"177","article-title":"Lymphocytes in schizophrenia patients under therapy: serological, morphological and cell subset findings","volume":"109","author":"Mazzarello","year":"2004","journal-title":"Ital J Anat Embryol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/j.1600-0447.1993.tb03452.x","article-title":"The profile of C-reactive proteins in functional psychotic states in a cohort in Nigeria","volume":"88","author":"Ohaeri","year":"1993","journal-title":"Acta Psychiatr Scand"},{"key":"B46","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.bbi.2011.07.240","article-title":"C-reactive protein is related to memory and medial temporal brain volume in older adults","volume":"26","author":"Bettcher","year":"2012","journal-title":"Brain Behav Immun"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1002\/hbm.22073","article-title":"Correlation between high-sensitivity C-reactive protein and brain gray matter volume in healthy elderly subjects","volume":"34","author":"Taki","year":"2013","journal-title":"Hum Brain Mapp"},{"key":"B48","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1192\/bjp.172.1.11","article-title":"Health of the Nation Outcome Scales (HoNOS)","volume":"172","author":"Wing","year":"1998","journal-title":"Br J Psychiatry"},{"key":"B49","doi-asserted-by":"publisher","first-page":"663","DOI":"10.4088\/JCP.v64n0607","article-title":"Chlorpromazine equivalent doses for the newer atypical antipsychotics","volume":"64","author":"Woods","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"B50","volume-title":"Statistical Power Analysis for the Behavioral Sciences.","author":"Cohen","year":"1988"},{"key":"B51","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0162-3109(99)00099-5","article-title":"The possible role of plasma kallikrein-kinin system and leukocyte elastase in the pathogenesis of schizophrenia","volume":"43","author":"Shcherbakova","year":"1999","journal-title":"Immunopharmacology"},{"key":"B52","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.eurpsy.2015.09.461","article-title":"Elevated C-reactive protein in schizophrenia inpatients is associated with aggressive behavior","volume":"31","author":"Barzilay","year":"2016","journal-title":"Eur Psychiatry"},{"key":"B53","doi-asserted-by":"crossref","first-page":"197","DOI":"10.4049\/jimmunol.190.Supp.197.2","article-title":"Antinuclear antibodies in general population: what does that mean?","volume":"190","author":"Raj","year":"2013","journal-title":"J Immunol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1093\/aje\/153.12.1183","article-title":"Distribution of serum C-reactive protein and its association with atherosclerotic risk factors in a Japanese population: jichi medical school cohort study","volume":"153","author":"Yamada","year":"2001","journal-title":"Am J Epidemiol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.drugalcdep.2013.08.027","article-title":"C-reactive protein and substance use disorders in adolescence and early adulthood: a prospective analysis","volume":"133","author":"Costello","year":"2013","journal-title":"Drug Alcohol Depend"},{"key":"B56","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/14622200801901997","article-title":"Association between cigarette smoking and C-reactive protein in a representative, population-based sample of adolescents","volume":"10","author":"O'Loughlin","year":"2008","journal-title":"Nicotine Tob Res"},{"key":"B57","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/mp.2015.11","article-title":"Adjunctive raloxifene treatment improves attention and memory in men and women with schizophrenia","volume":"20","author":"Weickert","year":"2015","journal-title":"Mol Psychiatry"},{"key":"B58","volume-title":"Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition","author":"First","year":"2002"},{"key":"B59","volume-title":"Wechsler Adult Intelligence Scale","author":"Wechsler","year":"1997"},{"key":"B60","volume-title":"Wechsler Test of Adult Reading","author":"Wechsler","year":"2001"},{"key":"B61","volume-title":"Neuropsychological Assessment.","author":"Lezak","year":"2004"},{"key":"B62","volume-title":"The Halstead-Reitan Neuropsychological Test Battery: Therapy and Clinical Interpretation","author":"Reitan","year":"1985"},{"key":"B63","volume-title":"Wechsler Memory Scale - Revised","author":"Wechsler","year":"1987"},{"key":"B64","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"B65","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1348\/014466505X29657","article-title":"The short-form version of the Depression Anxiety Stress Scales (DASS-21): construct validity and normative data in a large non-clinical sample","volume":"44","author":"Henry","year":"2005","journal-title":"Br J Clin Psychol"},{"key":"B66","volume-title":"SF-36 Health Survey: Manual and Interpretation Guide","author":"Ware","year":"2000"},{"key":"B67","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1192\/bjp.177.1.42","article-title":"Self-report quality of life measure for people with schizophrenia: the SQLS","volume":"177","author":"Wilkinson","year":"2000","journal-title":"Br J Psychiatry"},{"key":"B68","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamin","year":"1995","journal-title":"J R Stat Soc Series B Stat Methodol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-017-0962-y","article-title":"Using blood cytokine measures to define high inflammatory biotype of schizophrenia and schizoaffective disorder","author":"Boerrigter","year":"2017","journal-title":"J Neuroinflammation"},{"key":"B70","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1212\/01.WNL.0000073620.42047.D7","article-title":"Inflammatory markers and cognition in well-functioning African-American and white elders","volume":"61","author":"Yaffe","year":"2003","journal-title":"Neurology"},{"key":"B71","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/oxfordjournals.schbul.a033430","article-title":"Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the \u201cright stuff\u201d?","volume":"26","author":"Green","year":"2000","journal-title":"Schizophr Bull"},{"key":"B72","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1176\/appi.ajp.160.12.2209","article-title":"Complexity of prefrontal cortical dysfunction in schizophrenia: more than up or down","volume":"160","author":"Callicott","year":"2003","journal-title":"Am J Psychiatry"},{"key":"B73","doi-asserted-by":"publisher","first-page":"6454","DOI":"10.1073\/pnas.95.11.6454","article-title":"Cerebral cortical hyperactivation in response to mental stress in patients with cornary artery disease","volume":"95","author":"Soufer","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"B74","doi-asserted-by":"publisher","first-page":"246","DOI":"10.15585\/mmwr.mm6609e1","article-title":"Vital signs: prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation - United States, 2013-2015","volume":"66","author":"Barbour","year":"2017","journal-title":"Morb Mortal Wkly Rep."},{"key":"B75","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.jocn.2005.08.010","article-title":"C-reactive protein, but not homocysteine, is related to cognitive dysfunction in older adults with cardiovascular disease","volume":"13","author":"Gunstad","year":"2006","journal-title":"J Clin Neurosci"},{"key":"B76","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1164\/rccm.200610-1519OC","article-title":"C-reactive protein, obstructive sleep apnea, and cognitive dysfunction in school-aged children","volume":"176","author":"Gozal","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"B77","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1159\/000322092","article-title":"Systemic inflammation is associated with MCI and its subtypes: the Sydney memory and aging study","volume":"30","author":"Trollor","year":"2010","journal-title":"Dement Geriatr Cogn Disord"},{"key":"B78","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/j.1440-1819.2012.02354.x","article-title":"Cytokines in schizophrenia: Possible role of anti-inflammatory medications in clinical and preclinical stages","volume":"66","author":"Mansur","year":"2012","journal-title":"Psychiatry Clin Neurosci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02230\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T02:23:05Z","timestamp":1720664585000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02230\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,10]]},"references-count":78,"alternative-id":["10.3389\/fimmu.2018.02230"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.02230","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,10]]},"article-number":"2230"}}